Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.

Bersanelli, Melissa

Bersanelli, Melissa.

Bersanelli M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.

Immunotherapy ; 12(5): 269-273, 2020 04.

Article in English | MEDLINE | ID: covidwho-18230

Subject(s)

Betacoronavirus; Coronavirus Infections; Immunotherapy/adverse effects; Neoplasms; Pandemics; Pneumonia, Viral; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; COVID-19; Coronavirus Infections/etiology; Coronavirus Infections/immunology; Coronavirus Infections/physiopathology; Cytokine Release Syndrome; Disease Progression; Humans; Neoplasms/complications; Neoplasms/immunology; Neoplasms/therapy; Pneumonia, Viral/etiology; Pneumonia, Viral/immunology; Pneumonia, Viral/physiopathology; SARS-CoV-2

Keywords

anti-CTLA-4; COVID-19; SARS-CoV-2; anti-PD-1; anti-PD-L1; cancer patients; immune checkpoint inhibitors; immunotherapy; tocilizumab; viral infection

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Pandemics / Betacoronavirus / Immunotherapy / Neoplasms Topics: Long Covid Limits: Humans Language: English Journal: Immunotherapy Journal subject: Allergy and Immunology / Therapeutics Year: 2020 Document Type: Article Affiliation country: Imt-2020-0067

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google